Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
KalVista Pharmaceuticals, Inc. (DE:4XC1)
:4XC1
4XC1 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€6.95 - €13.80
Previous CloseN/A
Volume0.00
Average Volume (3M)111.00
Market Cap
€502.46M
Enterprise Value€350.00M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.28
Next Earnings
Mar 12, 2025EPS Estimate
-0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.35
Shares Outstanding49,417,988
10 Day Avg. Volume7
30 Day Avg. Volume111
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.70
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.06
Enterprise Value/Ebitda-2.10
Forecast
1Y Price Target
€23.21Price Target Upside155.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
KalVista Pharmaceuticals News
PremiumCompany Announcements
KalVista Pharmaceuticals Appoints New COO Amid Strategic Growth
PremiumCompany Announcements
KalVista Pharmaceuticals Reports Progress in HAE Treatment---
Bulls Say, Bears Say
Bulls Say
Drug Approval And Market PotentialSebetralstat is likely to be approved given the strength of the Phase 3 data and is expected to take substantial market share from current injectable drugs.
Market Growth And DifferentiationSebetralstat's oral dosing offers clear differentiation and the on-demand market in the US alone is worth approximately $1.5 billion, suggesting growth potential.
Physician And Patient InterestA survey showed that physicians think 48% of patients would want to use sebetralstat, indicating strong potential uptake.
Bears Say
Emerging CompetitionInvestors are possibly spooked by emerging competition from a second oral on-demand hereditary angioedema drug, Pharvaris' deucrictibant.
Investor ConcernsInvestors appear to be underestimating sebetralstat's prospects, possibly due to minor nuances of efficacy data.
Pipeline DevelopmentThe rest of the company's pipeline is still in preclinical stages, which may limit immediate growth prospects beyond sebetralstat.
---
Options Prices
Currently, No data available
---
Ownership Overview
11.87% Insiders
15.23% Mutual Funds
2.72% Other Institutional Investors
60.50% Public Companies and Individual Investors
4XC1 FAQ
What was KalVista Pharmaceuticals, Inc.’s price range in the past 12 months?
KalVista Pharmaceuticals, Inc. lowest stock price was €6.95 and its highest was €13.80 in the past 12 months.
What is KalVista Pharmaceuticals, Inc.’s market cap?
KalVista Pharmaceuticals, Inc.’s market cap is €502.46M.
When is KalVista Pharmaceuticals, Inc.’s upcoming earnings report date?
KalVista Pharmaceuticals, Inc.’s upcoming earnings report date is Mar 12, 2025 which is in 18 days.
How were KalVista Pharmaceuticals, Inc.’s earnings last quarter?
KalVista Pharmaceuticals, Inc. released its earnings results on Dec 05, 2024. The company reported -€0.868 earnings per share for the quarter, missing the consensus estimate of -€0.866 by -€0.002.
Is KalVista Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts KalVista Pharmaceuticals, Inc.’s price is currently Undervalued.
Does KalVista Pharmaceuticals, Inc. pay dividends?
KalVista Pharmaceuticals, Inc. does not currently pay dividends.
What is KalVista Pharmaceuticals, Inc.’s EPS estimate?
KalVista Pharmaceuticals, Inc.’s EPS estimate is -0.83.
How many shares outstanding does KalVista Pharmaceuticals, Inc. have?
KalVista Pharmaceuticals, Inc. has 49,417,988 shares outstanding.
What happened to KalVista Pharmaceuticals, Inc.’s price movement after its last earnings report?
KalVista Pharmaceuticals, Inc. reported an EPS of -€0.868 in its last earnings report, missing expectations of -€0.866. Following the earnings report the stock price went down -5.435%.
Which hedge fund is a major shareholder of KalVista Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in DE:4XC1
---
KalVista Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€23.21 (155.07% Upside)
€23.21 (155.07% Upside)
Blogger Sentiment
Bullish
DE:4XC1 Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $3.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.08%
12-Months-Change
Fundamentals
Return on Equity
-125.90%
Trailing 12-Months
Asset Growth
15.92%
Trailing 12-Months
Company Description
KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema (HAE) and diabetic macular edema (DME). The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello and is headquartered in Cambridge, MA.
---
4XC1 Stock 12 Month Forecast
Average Price Target
€23.21
▲(155.07% Upside)
Technical Analysis
BioCryst
―
FibroGen
―
AnaptysBio
―
Kiniksa Pharmaceuticals
―
Arcutis Biotherapeutics
―
Best Analysts Covering 4XC1
1 Year
1 Year Success Rate
11/20 ratings generated profit
1 Year Average Return
+12.99%
reiterated a buy rating 3 months ago
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +12.99% per trade.
---